Basic science highlights.
The 14th Conference on Retroviruses and Opportunistic Infections generated a lot of excitement with the announcement of clinical studies employing the use of 2 new classes of antiretroviral drugs that target the viral integrase enzyme and the viral coreceptor CCR5. In addition, a number of presentations on cellular restriction factors provided surprises regarding the mechanism by which cellular restrictions antagonize viral infection. There was also much interest in studies presenting novel cellular cofactors of HIV-1 infection. The conference illustrated how basic science research is paying off. Essential steps in the viral life cycle, uncovered through basic research, are now being targeted by new classes of antiviral agents. In addition, basic science is unveiling potential new targets of antiretroviral therapy.